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Although spring viremia of carp virus (SVCV) can cause high mortalities in common carp, 
a commercial vaccine is not available for worldwide use. Here, we report a DNA vaccine 
based on the expression of the SVCV glycoprotein (G) which, when injected in the muscle 
even at a single low dose of 0.1 µg DNA/g of fish, confers up to 100% protection against 
a subsequent bath challenge with SVCV. Importantly, to best validate vaccine efficacy, 
we also optimized a reliable bath challenge model closely mimicking a natural infection, 
based on a prolonged exposure of carp to SVCV at 15°C. Using this optimized bath 
challenge, we showed a strong age-dependent susceptibility of carp to SVCV, with high 
susceptibility at young age (3 months) and a full resistance at 9 months. We visualized 
local expression of the G protein and associated early inflammatory response by immuno-
histochemistry and described changes in the gene expression of pro-inflammatory cyto-
kines, chemokines, and antiviral genes in the muscle of vaccinated fish. Adaptive immune 
responses were investigated by analyzing neutralizing titers against SVCV in the serum of 
vaccinated fish and the in vitro proliferation capacity of peripheral SVCV-specific T cells. 
We show significantly higher serum neutralizing titers and the presence of SVCV-specific 
T cells in the blood of vaccinated fish, which proliferated upon stimulation with SVCV. 
Altogether, this is the first study reporting on a protective DNA vaccine against SVCV in 
carp and the first to provide a detailed characterization of local innate as well as systemic 
adaptive immune responses elicited upon DNA vaccination that suggest a role not only of 
B cells but also of T cells in the protection conferred by the SVCV-G DNA vaccine.
Keywords: Dna vaccination, spring viremia of carp virus, T cells, B cells, rhabdovirus
inTrODUcTiOn
The strong increase in the consumption or use of fish products over the last decades has been 
the result of the ongoing intensification of the whole aquaculture sector. This intensification, 
however, has led to the increasing incidence of infectious diseases for which no effective vaccines 
are yet available. In response to this, an increasing emphasis has been placed on the development 
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of experimental vaccines for fish and the investigation of fish 
immune responses after vaccination (1–5). Besides the various 
vaccination strategies currently employed in the aquaculture 
sector, including intraperitoneal injection or immersion vac­
cination, experimental DNA vaccination has been reported for 
a broad range of fish viruses and was shown to be especially 
effective against fish rhabdoviruses when administered by 
intramuscular injection. Furthermore, a major step forwards 
toward the commercialization of DNA vaccines for fish was 
made in April 2016 when the European Medicine Agency 
gave, for the first time, a positive advice toward their use in 
Europe by granting marketing authorization for the CLYNAV 
DNA vaccine against salmon pancreatic disease (6). Effective 
DNA vaccines against fish rhabdoviruses are reported against 
viral hemorrhagic septicemia virus (VHSV) in rainbow trout 
(Onco rhynchus mykiss) (7), Japanese flounder (Paralichthys 
oliva ceus) (8), turbot (Scophthalmus maximus) (9), and Pacific 
herring (Clupea pallasii) (10); against infectious hematopoi­
etic necrosis virus (IHNV) in Chinook salmon (Oncorhyn ­
chus tshawytscha), sockeye salmon (Oncorhynchus nerka) 
(11), and rainbow trout (12); and against hirame rhabdovirus 
in Japanese flounder (13). Furthermore, combined DNA vac­
cination against VHSV and IHNV was shown to induce pro­
tection against both viruses in rainbow trout (14). In all these 
successful vaccines, the DNA plasmid coded for the rhab dovirus 
glycoprotein (G).
Carp is the most cultured fish species worldwide, and the 
ornamental variant, koi carp, are very high value fish (15). Their 
production, however, is threatened by several bacterial and 
viral diseases. Among those, spring viramia of carp (SVC) is 
caused by SVC Virus (SVCV), a cytopathic virus belonging to 
the genus Vesiculovirus of the Rhabdoviridae family causing an 
acute systemic infection in several cyprinid species (16). SVC 
is widespread throughout Europe and has been diagnosed in 
other parts of the world including the US (17, 18) and China 
(19). SVCV virions contain one linear negative­sense single­
stranded RNA molecule that codes for five structural proteins. 
The G protein of SVCV, which is the only viral protein present 
on the virion surface and forms trimeric peplomers, binds to 
cellular receptors to induce viral endocytosis and is the target 
of protective neutralizing antibodies (16, 20, 21). Outbreaks of 
SVCV cause severe losses in carp production, especially during 
spring, and mainly affect juvenile carp for which mortality rates 
can be as high as 90% (16).
To date, DNA vaccines against SVCV have been shown to 
induce only limited protection (22, 23), much lower than reported 
for G protein­based DNA vaccines against other fish rhab­
doviruses including IHNV and VHSV (24). Recently, a recom­
binant Lactococcus plantarum expressing both the SVCV G protein 
and the koi herpes virus (cyprinid herpesvirus 3) Open Reading 
Frame 25 was reported to induce moderate protection against 
both viruses (25). While the aforementioned studies show the 
potential of G protein­based vaccines against SVCV, strong 
protection against SVCV viral challenge has not been reported 
thus far for any experimental vaccine. Furthermore, the lack of 
an optimized challenge model, closely resembling the natural 
route of SVCV infection, hampered vaccine evaluation as most 
studies report the use of intraperitoneal injections as the preferred 
challenge route.
Characterization of local and systemic immune responses 
after DNA vaccination against rhabdoviruses has been per­
formed for various fish species. A rapid induction of type­I 
interferons and interferon­stimulated genes (ISGs) such as mx, 
isg15, and viperin was reported in multiple studies (14, 26–28) 
and can therefore be considered one of the hallmarks of the rapid, 
non­specific, antiviral response induced by DNA vaccination. 
The rapid local upregulation of mx was suggested to be the main 
determinant for the observed cross­protection against IHNV 
after DNA vaccination using plasmids encoding the G protein 
of either snakehead rhabdovirus or SVCV (29). The expression 
of two microRNAs, which are strongly induced in rainbow trout 
either infected with VHSV or DNA vaccinated against VHSV, 
is apparently correlated with upregulation of type­I ifns, ifnγ, 
and mx genes and may play a role in the modulation of the 
response (30).
DNA vaccination of fish also induces an adaptive immune 
response. In trout, it was found that protection against VHSV 
was essentially based on the presence of neutralizing antibodies, 
which are detectable at 2–3 weeks after vaccination (14). T cell 
responses have also been studied, and it was shown that VHSV­G 
DNA vaccination induced a specific T cells response that com­
prised the same public response as induced by the virus itself 
(31). Furthermore, PBLs isolated from VHSV­G DNA vaccinated 
trout specifically killed VHSV­infected but not IHNV­infected 
target cells (32). To date, detailed characterization of the immune 
response of carp after DNA vaccination against SVCV has not 
been performed.
In this study, we report the establishment of a reliable 
SVCV bath challenge for common carp. Using this challenge 
model we first examined the age­related susceptibility of carp 
to SVCV, to estimate the best timing of vaccination and the 
window of high disease susceptibility. We found that carp were 
most susceptible at the age of 3 months and were fully resist­
ant at 9 months. Having assessed the importance of protecting 
carp at a young age, we vaccinated 3­month­old carp at 20°C, 
with two doses of an intramuscularly (i.m.) injected SVCV­G 
protein­based DNA vaccine, and showed the ability of the vac­
cine to induce 95–100% protection against SVCV, even when 
administered at a low dose (0.1 µg/g fish). To investigate the 
rapid local immune response induced after DNA vaccination, 
we raised an antibody against the SVCV G protein and used 
it together with leukocyte­specific antibodies to examine the 
expression of the G protein in the muscle and the recruitment 
of leukocytes to the site of injection. By real­time quantitative 
PCR (RT­qPCR) we characterized the expression of a panel 
of immune genes related to the innate and adaptive response. 
Through analysis of virus­specific humoral and cellular 
responses we investigated the neutralizing activity in serum of 
vaccinated fish and the presence of antigen­specific T­cells by 
performing an in vitro proliferation assay.
Altogether, this is the first study reporting (1) a reliable SVCV 
bath challenge model, (2) age­related susceptibility of carp to 
SVCV, (3) the optimization of a G protein­based DNA vaccine 
conferring full protection against SVCV, and (4) the detailed 
3Embregts et al. DNA Vaccination of Carp against SVCV
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1340
characterization of local as well as systemic humoral and cellular 
immune responses triggered upon DNA vaccination in carp. 
Overall, this report contributes to the understanding of the pro­
tective mechanisms triggered by DNA vaccination in carp and 
will play an essential role in the design of future SVCV­G­based 
vaccination strategies in carp, the species representing the biggest 
fish production in the global aquaculture.
MaTerials anD MeThODs
animals
European common carp (Cyprinus carpio carpio) R3  ×  R8 
were used that originated from a cross between the Hungarian 
R8 strain and the Polish R3 strain (33). In this study, we will 
refer to carp as the European common carp subspecies, unless 
stated otherwise. Carp were bred in the Aquatic Research Facility 
(ARC) of University’s animal facility, Carus at Wageningen 
University, the Netherlands and were either kept at the local 
facility, transported to the Veterinary Research Institute (VRI, 
Brno, Czech Republic), or to the Institut National de la Recherche 
Agronomique (INRA, Paris, France) for viral challenge experi­
ments. Carp were raised at 20–23°C in recirculating UV­treated 
water and fed pelleted carp food (Skretting, Nutreco) twice 
daily.
Virus
The reference SVCV strain VR­1390, isolate stock of the INRA 
laboratory (34, 35), was propagated in epithelioma papulosum 
cyprinid (EPC) cells grown in Glasgow’s modified Eagle’s 
medium (GMEM)–25  mM HEPES (Eurobio) supplemented 
with 10% fetal calf serum (FCS; Eurobio), 1% tryptose phosphate 
broth (Eurobio), 2 mM l­glutamine (PAA), 100 µg/mL penicil­
lin (Biovalley), and 100  µg/mL streptomycin (Biovalley) in the 
absence of CO2. The SVCV CAPM V 539 strain (36) was propa­
gated in common carp brain (CCB) cells at 27°C or in EPC cells at 
20°C. EPCs were grown in MEM medium (Gibco) supplemented 
with 10% FCS, 2  mM l­glutamine, 100  µg/mL penicillin, and 
100 µg/mL streptomycin in the presence of CO2. For CCBs, the 
same medium was supplemented with 3.5 g/L d­glucose and 1% 
non­essential amino acids (Gibco). Virus titers were determined 
by the method of Reed and Muench (37) and were given as 
plaque­forming units (pfu).
characterization and Validation of  
a Monoclonal antibody against the  
sVcV g Protein
Spring viremia of carp virus of the Fijian strain (35, 38) was 
used to raise antibodies against the SVCV G protein in mice. 
Before immunization, female Balb/c mice were given a toler­
izing treatment to reduce reactions to cell proteins, as described 
before (39). After such treatment, mice were immunized with 
1.4 ×  108  pfu of concentrated and purified SVCV in complete 
Freund’s adjuvant. The same viral dose was given 4 weeks later 
in incomplete Freund’s adjuvant, followed by two more doses in 
the following 85  days. Three days after the last immunization 
mouse spleen cells were isolated and fused with Sp2/0 myeloma 
cells. Obtained hybridoma supernatants were screened through 
Western blot and immunofluorescence of SVCV infected and 
pcDNA3­SVCV­G transfected cells. For Western blot analysis, 
purified SVCV and lysates from non­infected EPC cells were 
resolved on 15% SDS­PAGE gels. Proteins were transferred to 
nitrocellulose membranes and incubated with hybridoma super­
natants (1:10) or with an available anti­SVCV rabbit polyclonal 
serum (1:2,000) as positive control. Western blot development 
was performed as described before (38, 39). For immunofluores­
cence analysis, EPCs were infected with an MOI of 1 for 24 h at 
20°C. In parallel, EPCs were seeded in 6­well plates, transfected 
with 2 µg of pcDNA3­SVCV­G or pcDNA3 using 7 µL of FuGENE 
HD (Promega) following the manufacturer’s guidelines. EPC 
was imaged 48 h after transfection. Infected or transfected cells 
were fixed with 4% PFA for 15 min at 4°C and incubated with 
hybridoma supernatant from selected clone 13C10c (1:150) 
for 1  h and with goat­anti­mouse­RPE (BioLegend, 1:500) for 
30  min at room temperature. A counterstaining with DAPI 
(Thermo Scientific) was included to stain the cells nuclei. Images 
were acquired with an EVOS fl LED fluorescence microscope 
(Advanced Microscopy Group).
Optimization of sVcV challenge
For all viral challenges the water temperature was gradually 
lowered from 20 to 15°C at a rate of 1–2°C/day. Optimization of 
the SVCV challenge was performed at INRA, using the VR­1390 
strain. Three­month­old carp (n =  20 per group, 2–4  g) were 
challenged by immersion, i.m. or intraperitoneal (i.p.) injec­
tion. For immersion challenge, carp were exposed to a dilution 
of SVCV­containing EPC supernatants (8  ×  106  pfu/mL) for 
either 3 or 48 h in a volume of 4 L (biomass 15 g/L). A control 
group (n  =  20) was exposed to uninfected EPC cell culture 
supernatant by immersion and was treated similarly. Fish were 
also challenged by injection; they were anesthetized using 0.3 g/L 
tricaine methane sulfonate (TMS, Crescent Research Chemicals) 
before i.m. injection of 1,000 pfu/fish or i.p injection of 5,000 or 
10,000 pfu/fish. Water quality monitoring included pH (8) and 
oxygen (>7 mg/L). Fish were observed daily, and moribund fish 
were removed from the tanks.
Age­related sensitivity to SVCV infection was investigated 
at VRI, using the SVCV CAMP V 539 strain and juvenile carp 
between 3 and 9 months (20 g). R3 × R8 carp, all from the same 
hatching batch, were raised under the same condition [water 
flow (15  L/h) pH (7.5–8), oxygen (10–12  mg/L), and N­NH4 
(<0.2  mg/L)] up until 3  months of age. At that time, a sub­
group of fish (n = 20 per group) was transferred to 100 L tanks 
having the same water conditions, were acclimatized to the 
temperature of 15°C and challenged by immersion for 30 h with 
8 × 106 pfu/mL. The remaining fish were kept under controlled 
water quality condition up until 7 and 9 months, and then chal­
lenged following the same protocol. Fish were observed daily, 
and moribund fish were removed from the tanks.
Dna Vaccination
The pcDNA3­SVCV­G DNA vaccine was prepared as described 
previously (32) using the G­protein sequence of the CAPM V 
539 strain Jaroslavicky 97 (accession number: KU934300). 
TaBle 1 | Primers used in real-time quantitative PCR.
Primer FW primer 5′–3′ rV primer 3′–5′ acc. no.
housekeeping genes
40s CCGTGGGTGACATCGTTACA TCAGGACATTGAACCTCACTGTCT AB012087
β-actin CAACAGGGAAAAGATGACACAGATC GGGACAGCACAGCCTGGAT CCACTBA
sVcV detection
svcv-n TGAGGTGAGTGCTGAGGATG CCATCAGCAAAGTCCCGGTAT NC_002803
cytokines
cxca CTGGGATTCCTGACCATTGGT GTTGGCTCTCTGTTTCAATGCA AJ421443
cxcb1 GGGCAGGTGTTTTTGTGTTGA AAGAGCGACTTGCGGGTATG AB082985
cxcb2 AGGCAGGTGCTTCTGTGCTGACA TTCATGCATTTCCGCTCTGCGCT JN104598
il1β AAGGAGGCCAGTGGCTCTGT CCTGAAGAAGAGGAGGAGGCTGTCA AJ245635
il6a CAGATAGCGGACGGAGGGGC GCGGGTCTCTTCGTGTCTT KC858890
il6b GGCGTATGAAGGAGTGAGGG TGCTCCTCTCTCGGTCAGAT KC858889
tnfα GCTGTCTGCTTCACGCTCAA CCTTGGAAGTGACATTTGCTTTT AJ311800 and AJ311801
Transcription factors
stat1 GAGACGGAGGAATCACC GGATGTCTGGGTAAAGGTAG KJ782028
interferons
ifnγ2a/2b CGATCAAGGAAGATGACCCAGTC GTTGCTTCTCTGTAGACACGCTTC AM168523
ifnφ1 GCACGTATACAAAGATGAACC TGATCCAAGGTCAAGACAAG GQ168341
ifnφ2 TTGGTGTAAAAAAGGCAACC GCTGCTTTCTCGTCATAATAC JN741616
interferon-stimulated genes
mx1 ACAATTTGCGGTCTTTGAGA CCCTGCCATTTCTCTTCG cypCar_00015892
mx2 GCTTACGGTCTCTGGGG TGGTTTCATCTTTAGTTCTTATCATC cypCar_00029512
vip2 CTGTCGGACACATCAGC TCAATGGGCAAGACGAAA cypCar_00024055
pkr3 CACGGTGTTTGAAAAGAGC GACTGGGTCTCAGCATTC cypCar_00039221
isg15.2 AGTGTTCGTCAAGAATGAGG CCTCGCAGACGGAAAAC cypCar_00039111
adaptive immune genes
igm CACAAGGCGGGAAATGAAGA GGAGGCACTATATCAACAGCA AB004105
igt1 AAAGTGAAGGATGAAAGTGT TGGTAACAGTGGGCTTATT AB598367
igt2 GATTCTACTGGGT8CTTCAC GACATCACTCAACTC8TTCT AB598368
zap70 GGAACAAGCCATCATTAGCC GTCGTCTCTCACCCTCCTG Scaf 2523 and 63374
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All vaccinations were performed at 20°C. Carp of 3  months 
(n = 10 per group, 1.5–2 g) were assigned to either the pcDNA3 
empty plasmid group (negative control) or the pcDNA3­SVCV­
G group (vaccine). Carp were anesthetized in 0.3 g/L TMS and 
vaccinated i.m. in the epaxial muscle, below the dorsal fin with 
1 µg (first experiment) or 0.1 µg (second experiment) of DNA 
plasmid/g of fish in 10 µL PBS.
For assessment of vaccine efficacy, carp were challenged 
2.5–3  months after vaccination, at 15°C, using the optimized 
challenge method, and survival was monitored over a period 
of 3–5  weeks. In parallel, mid kidneys were isolated from a 
subgroup of carp (n =  6) to confirm SVCV infection through 
analysis of svcv n gene expression. The mid kidney is one of the 
organs in which virus replication occurs, even early after infec­
tion and can be used for virus re­isolation of monitoring of viral 
infection (40).
rna isolation and cDna synthesis
For gene expression analysis of the local response at the injec­
tion site, carp injected with the low plasmid dose (0.1  µg/g 
fish) were sacrificed at 3 and 5 days postinjection (dpi). Carp 
were euthanized in 0.6 g/L TMS and bled through the caudal 
vein. Muscle at the injection site was isolated, immediately 
snap frozen in liquid nitrogen, and stored at −80 until further 
processing. Total RNA was isolated from muscle and mid 
kidney tissue using the RNeasy Mini Kit (Qiagen) according 
to the manufacturer’s instructions including on­column DNase 
treatment using the RNase­free DNase set (Qiagen). For RNA 
isolation from muscle tissue, an additional Proteinase­K 
(Qiagen) treatment was included. RNA concentrations were 
measured using a Nanodrop­1000, the integrity was verified on 
a 1% agarose gel and RNA was stored at −80°C until further 
use. Before cDNA synthesis of 1 µg total RNA, a second DNase 
treatment was performed using DNAse I, Amplification Grade 
(Invitrogen). Reverse transcription of the RNA was performed 
using random primers (300 ng) and Superscript™ III (200 U) 
First Strand Synthesis Systems for RT­PCR (Invitrogen). cDNA 
samples were further diluted 25 times in nuclease­free water and 
stored at −20°C.
gene expression analysis
Real­time quantitative PCR was performed using a Rotor­
Gene™ 6000 (Qiagen). Fluorescence data were analyzed using 
Rotor­Gene Q series software version 2.3.1. Briefly, 5 µL of 25 
times diluted cDNA was mixed with 2 µL of forward and reverse 
primers (2.1 µM of each primer) and 7 µL of 2× ABsolute qPCR 
SYBR Green Mix (Thermo Scientific) as detection chemistry. The 
list of primers can be found in Table 1. The take­off value for 
each sample and the average reaction efficiencies (E) for each 
primer set were obtained upon comparative quantitation analysis 
from the Rotor­Gene software (41). The relative expression ratio 
(R) of each sample was calculated according to the Pfaffl method 
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(42) based on the take­off deviation of sample versus each of the 
unhandled controls at time point 0 h and normalized relative to 
the s11 protein of the 40s subunit as reference gene. For analysis 
of the svcv­n gene during infection with SVCV, the housekeeping 
gene β­actin was used, since it was found to be the most stable 
under these circumstances.
immunohistochemistry
To visualize the expression of the SVCV G protein at the site 
of injection, carp (3–4  g) were i.m. injected with 20  µg of 
pcDNA3 (empty plasmid) or pcDNA3­SVCV­G plasmid in 
20  µL PBS containing 0.01% green tattoo dye (Eickemeyer). 
Carp were sacrificed 7 and 14  days dpi and bled through 
the caudal vein before collecting muscle tissue at the site of 
injection.
Cryosections (5 µm) from muscle sections were stained with 
specific antibodies as described before (43). For the detection of 
the SVCV­G protein, slides were stained with anti­SVCV­G clone 
13C10c diluted 1:150 and alkaline phosphatase (AP) conjugated 
goat­anti­mouse (Dako) (1:200). Development was performed 
using AP substrate [4.5 µL/mL nitro­blue­tetrazolium (Roche 
Applied Science) and 3.5 µL/mL 5′­bromo­4′­chloro­3′indolyl 
phosphatase (Roche Applied Science) in AP buffer (0.1  M 
Tris–Cl, 0.1  M NaCl, 0.05  M MgCl2) until sufficient staining 
was observed]. For the detection of neutrophilic granulocytes, 
slides were stained with the TCLBE8 antibody [1:50 (43, 44)] 
and GAM­AP (1:200, Dako). Development was performed as 
described earlier. Tissue morphology was examined using a 
Hemacolor® eosin­azur staining (Merck Millipore). Pictures 
were made using a Leica DM6 microscope and analyzed using 
the Leica LAS X program.
neutralization assay
Sera from fish injected with 1  µg/g of either pcDNA3 or 
pcDNA3­SVCV­G plasmid were collected 2.5–3  months after 
vaccination and were used to quantify neutralizing titers. 
Blood was drained from the caudal vein and was let to clot at 
4°C overnight. Serum extraction was performed by centrifuga­
tion at 2,000  g for 10  min, and the obtained supernatant was 
centrifuged at 10,000 g for 20 min. Serum was heat­treated at 
56°C for 30 min, aliquoted and frozen at −20°C before use in 
titration assays. To determine SVCV neutralization titers, carp 
serum was mixed with an equal volume of GMEM 2% FCS, 
DEAE 1× (Sigma), containing carp complement (standardized 
serum pool from naïve carp, diluted 1:80), and incubated 4 h at 
20°C with 2.1 × 102 pfu SVCV (strain VR­1390). One hundred 
microliters of the mixture were then transferred onto confluent 
EPC monolayers in 24 wells and incubated for 1 h at 14°C. After 
this step, melted methylcellulose was added to the wells, and 
plates were kept at 24°C for 3 days. After 3 days, plates were fixed 
with 4% formaldehyde and stained with crystal violet to reveal 
viral plaques. Controls included non­infected wells and wells 
infected with SVCV without preincubation with carp serum. 
Plaques were counted manually and an upper threshold on the 
number of counted plaques, indicating a fully infected well, was 
set at 100 plaques.
In Vitro antigen-specific B and T cell 
Proliferation assays
Carp were vaccinated i.m. with 1 µg DNA/g of fish of pcDNA3­
SVCV­G DNA vaccine. The same amount of pcDNA3 plasmid 
was used as injection control. PBLs were isolated 3  months 
after vaccination, separated on Ficoll Paque (GE Healthcare) as 
described previously (45, 46), and stained with carboxyfluores­
cein succinimidyl ester (CFSE) (47). Part of the CFSE­labeled 
cells (2 × 107 cells/mL) was transferred to round­bottom 96­well 
culture plates (Corning) and stimulated with SVCV (MOI of 25) 
or, as a control, with equivalent volumes of CCB­conditioned 
culture medium, for 2  h at 27°C. Cells were then seeded in 
48­well plates (Corning) at a density of 2 × 106/well in Advanced 
DMEM/F­12 (Life Technologies) supplemented with 2  mM 
l­glutamine, 100  U/mL penicillin G, 50  mg/mL streptomycin 
sulfate, 1% FCS, and 10−5 M 2­mercaptoethanol (Sigma). In paral­
lel, a fraction of both SVCV­treated or mock­treated cells was 
incubated in the presence of recombinant carp interferon gamma 
(Ifnγ2, 100  ng/mL) or interleukin­10b (rIl10b, 0.25  U/mL) 
since we reported before that these cytokines are able to enhance 
carp leukocytes pro­inflammatory activities (48) and (antigen­
specific) proliferation of memory cells (47, 49–51). Cells were 
incubated for 6 days at 27°C in the presence of 5% CO2.
Proliferation of Zap70+ T cells and Igm+ B cells was analyzed 
by flow cytometry using a cross­reactive antibody for the pan 
T cell marker Zap70 (47) and the mouse monoclonal antibody 
(WCI12) against carp Igm (52). Cells were collected after 6 days, 
washed once with PBS and incubated for 30  min at RT with 
Zombie Red™ fixable viability dye (1:1,000 in PBS, BioLegend). 
For the subsequent analysis of T  cell proliferation, cells were 
washed once with FACS buffer [0.5% BSA (Roche), 0.01% NaN3 
in PBS] and were fixed and permeabilized using the Cytofix/
Cytoperm Kit (BD Biosciences) according to the manufacturer’s 
protocol. Cells were washed once in FACS buffer and incubated 
for 30  min on ice in 35  µL of anti­Zap70 rabbit mAb (99F2; 
Cell Signaling, 1:100). After two washes with FACS buffer, cells 
were incubated in 35 µL of PE­conjugated goat­anti­rabbit IgG 
(Santa Cruz, 1:100). For B cell proliferation, cells were washed 
and incubated as described earlier with WCI12 mAb (1:100) and 
goat­anti­mouse IgG­PE (Santa Cruz, 1:100). After subsequent 
washes, cells were analyzed on a FACS CantoA (BD Biosciences), 
and data were analyzed using FlowJo V10 (BD Biosciences). 
Proliferation of B or T cells was analyzed by first gating on the 
live cells (Zombie Red™, negative) subsequently for the specific 
cell staining (either WCI12 for Igm+ B cells or Zap70+ for total 
T cells, PE channel), and finally for the CFSE staining (visible 
in the FITC channel) of the identified population. The intensity 
of the CFSE staining at day 0 was used to set the thresholds for 
proliferation. At day 6, a decrease in CFSE fluorescence intensity 
was indicative of cell proliferation. Obtained percentages of 
proliferation in each treated group were corrected with their 
respective conditioned medium­only control by subtraction.
statistical analysis
Statistical analysis was performed for gene expression, neutrali­
zation assay, and proliferation assay data. All data were analyzed 
FigUre 1 | Establishment of a bath challenge for spring viremia of carp virus (SVCV) and validation of a protective DNA vaccine. (a) Carp (n = 20/group) of 
3 months were acclimatized to a temperature of 15°C, exposed to the indicated doses of SVCV (VR-1390 strain), for the indicated time, and mortality was recorded. 
(B) Carp (n = 10) were challenged at 3, 7, or 9 months of age by bath for 30 h at 15°C using 8 × 106 pfu/mL of the CAPM V 539 SVCV strain, and mortality was 
recorded. (c) Three-month-old carp (n = 10/group) were i.m. injected with 1 µg/g of fish of either pcDNA3 or pcDNA3-SVCV-G and challenged 2.5 months 
postvaccination, for 48 h at 15°C using 8 × 106 pfu/mL SVCV (VR-1390). In a subsequent experiment, fish were vaccinated with 0.1 µg/g of fish of the same 
plasmids and challenged as described previously. Survival was monitored over a period of 4 weeks. (D) Carp were treated as in panel (c) using 1 µg/g of fish of 
DNA plasmid, and upon challenge mid kidneys were isolated at the indicated time points. svcv-n gene expression was analyzed by real-time quantitative PCR. Gene 
expression was normalized relative to β-actin as a housekeeping gene and expressed relative to the unhandled controls collected at time point 0 h. Data are shown 
as average + SD of n = 6 fish. Abbreviation: d, day.
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using SPSS Software 22 (IBM). For gene expression data, relative 
expression ratios R were transformed [LN(R)], and significant 
differences (p <  0.05) between pcDNA3 and pcDNA3­SVCV­
G at the indicated time point were determined by a one­way 
ANOVA followed by the Tukey post  hoc test. Plaque count of 
the neutralization assay and the percentages of proliferating 
Zap70+ T cells from the proliferation assay were analyzed using a 
one­way ANOVA.
resUlTs
Prolonged exposure of Juvenile carp  
to sVcV at 15°c results in a reliable  
Bath challenge Model of infection
To evaluate vaccine efficacy, the establishment of a reliable 
and reproducible infection model is of utmost importance. 
To the best of our knowledge, the first optimization of an 
SVCV bath challenge was described in 1978 by Ahne (53) 
exposing 25–30  g carp fish to 2 ×  103  pfu for 2  h at 13°C. 
Subsequent reports describe similar procedures. In our hands, 
however, such protocol resulted in high variability between 
replicate challenges and generally low mortality rates (data 
not shown). Therefore, we first established a reliable and 
robust (bath) infection model closely mimicking the natural 
route of virus infection. We initially investigated the effect of 
virus dose, time of exposure and infection route on infection 
efficacy.
Carp of 3 months were exposed to SVCV (VR­1390 strain) 
by i.m. or i.p. injection as well as by bath at a temperature of 
15°C. Challenge by i.m. or i.p. injection resulted in morta lity 
rates of 35 and 15–25%, respectively, independent of the viral 
dose used (Figure 1A). Similar mortality rates were observed 
after bath challenge for 3  h at 8  ×  106  pfu/mL. Bath chal­
lenge using the same viral load but with an exposure time of 
48  h resulted in high mortality (up to 90%) within 15  days. 
Altogether, the data indicate that prolonged exposure of juve­
nile carp to SVCV, in a bath challenge at 15°C, results in high 
mortality rates.
Using the optimized bath challenge method, we next 
investigated the effect of age on SVCV susceptibility to look 
for the best time window to later on investigate vaccine effi­
cacy. To test the robustness of the bath challenge, we used the 
closely related SVCV CAMP V 539 strain in an interlaboratory 
experimental setup. For this, 3, 7, or 9­month­old carp were 
exposed to 8 × 106 pfu/mL of the CAPM V 539 SVCV strain 
by bath for 30  h at 15°C. A strong age­dependent effect on 
disease susceptibility was observed (Figure  1B). While again 
up to 90% mortality could be observed in 3­month­old carp, 
mortality rates rapidly decreases to 50% in 7­month­old fish, 
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and only 0–20% mortality was observed in 9­month­old carp. 
Altogether, we developed a reliable bath challenge with opti­
mized temperature, viral load, and exposure time. Using this 
optimized bath challenge, we show that susceptibility of carp 
to SVCV is age dependent, and that the optimized challenge is 
reliable independent on the viral strain used.
intramuscular Vaccination Using a g 
Protein-Based Dna Vaccine induces 
95–100% Protection against sVcV, even 
When administered at a low Dose
Optimization of the bath challenge model showed that carp 
are most susceptible to SVCV at young age (between 3 and 
6 months). Therefore, to test the efficiency of DNA vaccination, 
carp were vaccinated at an age of 3  months and subsequently 
challenged at an age of 6 months (2.5–3 months after vaccina­
tion). This assured that we were still within the age window 
of high susceptibility to SVCV (<6 months), but also that the 
strong non­specific, type­I IFN­dependent protection induced 
by DNA vaccination in fish would have faded (24).
Carp were vaccinated at 20°C with 1  µg of pcDNA3­
SVCV­G/g fish and challenged 2.5 months later at 15°C using 
the aforementioned bath challenge. While survival in the 
pcDNA3­injected group was around 40%, the pcDNA3­SVCV­ 
G­vaccinated group had 90% survival (Figure  1C), which 
is equivalent to a relative percent survival (RPS) of 83.3. 
To investigate whether a lower dose of vaccine would be suffi­
cient to protect against SVCV, in a subsequent experiment carp 
were vaccinated with 0.1 µg of the vaccine per gram of fish and 
challenged as described. In this experiment, full protection 
(100 RPS) in the vaccinated group was observed 2.5  months 
after vaccination (Figure  1C). In the group vaccinated with 
the high vaccine dose, the development of an SVCV infection 
was verified by analysis of the SVCV N gene expression in mid 
kidneys of vaccinated and non­vaccinated fish after SVCV 
challenge. Svcv n gene expression was detected from 2  days 
postinfection onward in non­vaccinated fish (pcDNA3) but not 
in vaccinated fish (pcDNA3­SVCV­G) (Figure 1D), confirming 
that vaccination with the pcDNA3­SVCV­G vaccine strongly 
suppressed SVCV infection. No expression of the N gene was 
observed in non­challenged fish (data not shown). Altogether, 
the results indicate that the pcDNA3­SVCV­G vaccine, even at 
a low dose of 0.1 µg/g fish, is able to confer protection against 
SVCV for a period long enough to cover the age window during 
which carp are most susceptible to SVCV.
sVcV-g Protein is expressed in the 
Muscle after Dna Vaccination and 
Triggers a strong local immune response
To visualize the expression of the SVCV G protein after i.m. 
administration, and to investigate the tissue damage as well as the 
local immune response, carp were injected with 20 µg of either 
pcDNA3 or pcDNA3­SVCV­G plasmid. Muscle tissue from the 
site of injection was excised at 7 and 14 dpi from both groups, 
and the anti­SVCV­G antibody (characterized and validated 
in Figure S1 in Supplementary Material) was used to visualize 
G­protein expression. To visualize the influx of leukocytes after 
vaccination a Hemacolor® eosin­azur staining was used, as well 
as specific antibody staining for neutrophilic granulocytes and 
macrophages. A strong influx of leukocytes was observed at 7 dpi 
in muscle tissue of both pcDNA3 injected (Figure  2A, 2) and 
pcDNA3­SVCV­G vaccinated group (Figure 2A, 3), indicating 
that the influx is strongly damage­ and inflammation­driven, 
mainly caused by the injection itself. Myocytes expressing the 
viral G protein on their cell membrane were detected at 7 as well 
as 14 dpi (Figure 2B, 2–3 and Figure 2C). At 7 dpi, myocytes 
expressing the G protein were found to be surrounded by a large 
number of leukocytes and were disconnected from neighboring 
cells. Furthermore, the leukocytes appeared to infiltrate myocytes 
positive for G­protein expression (Figure 2B, 3, black arrows).
To verify the presence of specific leukocytes subtypes in the 
area surrounding the G protein­expressing cells, an antibody 
specific to neutrophilic granulocytes was used (Figure  2B, 
4–6). An influx of neutrophils was observed at 7 dpi in muscle 
injected with the pcDNA3 plasmid (Figure 2B, 4) and to a larger 
extent in the pcDNA3­SVCV­G injected tissue (Figure 2B, 5–6). 
Moreover, the neutrophil­specific staining revealed that a large 
proportion of leukocytes surrounding G protein­expressing 
myocytes are neutrophils. Macrophages were recruited to the 
site of injection at this time point as well, but in lower numbers 
than neutrophils (data not shown).
A prominent change in muscle morphology at the injec­
tion site was observed at 14  dpi, with a clear deterioration of 
the muscle tissue. At this time point, the G protein­expressing 
myocytes were condensed, as indicated by the concentrated 
G­protein staining, detached from the surrounding myocytes 
and completely surrounded by leukocytes (Figure 2C).
In conclusion, we found an injection­related inflammation 
in the muscle. G protein­expressing myocytes were clearly sur­
rounded by large numbers of leukocytes, especially neutrophils. 
At 14 dpi a complete isolation of the G protein­expressing myo­
cytes from the surrounding muscle tissue was observed, along 
with cell condensation. Altogether, this suggests that G­protein 
expression in the tissue leads to a robust response against G 
protein­expressing cells, which in turn might favor activation 
of protective mechanisms.
intramuscular Dna Vaccination induces  
a rapid Upregulation of immune-related 
genes at the site of injection
Given the high protection conferred by the DNA vaccine 
plas mid (Figure  1C), and the strong inflammatory response 
observed locally at the site of injection at 7 and 14 dpi (Figure 2), 
we next investigated the early local gene expression profile 
induced by vaccination. A panel of pro­inflammatory cytokines 
and chemokines, antiviral genes as well as adaptive immune 
markers, were selected to reveal which pathways were activated 
before the observed leukocyte recruitment (Figure  2). Carp 
were injected with 0.1  µg/g plasmid, and muscle tissue at the 
site of injection was isolated at 3 and 5 dpi for subsequent gene 
expression analysis (Figure 3).
FigUre 2 | Immunohistochemical analysis of G-protein expression and leukocyte recruitment after DNA vaccination. Carp were injected with 20 µg of pcDNA3  
or pcDNA3-spring viremia of carp virus (SVCV)-G. (a) Muscle was isolated at the site of injection at 7 days postinjection (dpi), and cryosections (5 µm) were stained 
with Hemacolor® (eosin-azur) to visualize leukocyte recruitment in non-injected (A.1), pcDNA3 injected (A.2), or pcDNA3-SVCV-G injected (A.3) tissue. (B) Muscle  
at the site of injection was isolated 7 dpi from carp injected with pcDNA3 (B.1) or pcDNA3-SVCV-G (B.2–3) and stained with anti-SVCV-G antibody (clone 13C10c). 
Green asterisks in panel (B.1) indicate ink particles along the needle path. Brown color in panel (B.2) indicates G-protein expression. Note that the G protein-
expressing cell is detached from the rest of the tissue and surrounded by leukocytes. A magnification of panel (B.2) shows the G-protein reactivity [(B.3), purple/
brown color] on the myocyte surface and the presence of leukocytes around and infiltrating (black arrows) the myocyte. A consecutive slide of the tissue at the  
same time point was stained using an antibody specific for carp neutrophilic granulocytes (B.4–6); the inset in panel (B.5) identifies the same G protein-expressing 
cell as in panels (B.2,B.3). (c) Muscle at the site of injection isolated 14 dpi was stained as described in panels (B.1–3); (C.1) overview of the muscle area in which 
four G protein-expressing myocytes could be detected; (C.2–5) higher magnification of the areas indicated by the insets in panel (C.1); note the condensation of  
the G-protein staining (purple color) and the presence of leukocytes surrounding the G protein-expressing myocytes. Scale bars indicate distance (in µm).
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FigUre 3 | Gene expression analysis of the local immune response after i.m. DNA vaccination against spring viremia of carp virus (SVCV). Carp were injected with 
0.1 µg/g of either pcDNA3 or pcDNA3-SVCV-G. Muscle tissue at the site of injection was excised at 3 and 5 days postinjection (dpi). Expression of the indicated 
immune-relevant genes was normalized against the housekeeping gene s11 of the ribosomal subunit 40S and expressed relative to the unhandled control at time 
point 0 h. Asterisks (*) indicate significant differences (p < 0.05) between the pcDNA3 and pcDNA3-SVCV-G group at the respective time point as assessed by 
one-way ANOVA, followed by a Tukey post hoc test. Bars indicate average and SD of n = 3 fish per time point.
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At 3  dpi, the chemokine cxcb1 (54, 55) and the cytokines 
infγ2ab and ifnφ2 were specifically upregulated by the injection 
of pcDNA3­SVCV­G plasmid (vaccine group), but not by the 
empty plasmid. At 5 dpi, ifnφ1 was also significantly upregulated 
in the vaccine group. By contrast, in both the pcDNA3 and in 
the pcDNA3­SVCV­G injected groups, the pro­inflammatory 
molecules cxcb2, tnfα, il6b, and il1β and the antiviral genes mx1, 
mx2, vip2, pkr3, stat1, and isg15.2 were all elevated at 3  dpi. 
The overall upregulation of pro­inflammatory genes confirmed 
the previous observation (Figure  3) that a local inflammatory 
response marked by a strong recruitment of leukocytes is trig­
gered in part by the damage caused by the injection and by the 
plasmid backbone, and in part is specific for the vaccine plasmid. 
Interestingly, when looking at markers of adaptive immune 
cells, a vaccine­specific upregulation was observed at 3 dpi for 
igt1 and zap70, whereas igm transcripts were elevated, but not 
significantly compared with the control group, altogether sug­
gesting that pcDNA3­SVCV­G promoted an early recruitment 
of B and T cells at the site of injection. At 5 dpi, the increased 
expression of these markers was no longer specific for the vaccine 
as transcription was elevated in both the pcDNA3 and pcDNA3­
SVCV­G injected group.
Altogether, our results indicate that injection of plasmid 
DNA in the muscle of carp induces a strong local inflamma­
tory response, that is, in part specific for the vaccine plasmid. 
Considering the efficacy of the DNA vaccine (Figure  1C), the 
combined inflammatory response induced by the damage, the 
plasmid backbone and in part by the SVCV­G protein, might all 
contribute to provide the optimal conditions for the onset of a 
specific adaptive response to the SVCV­G protein.
Dna Vaccination against sVcV leads  
to Detectable Virus neutralizing Titers  
in the serum of Vaccinated Fish
To investigate the role of humoral responses induced by i.m. 
DNA vaccination, we analyzed the neutralizing capacity of 
serum from vaccinated carp 3 months after vaccination. This is 
FigUre 4 | Neutralizing capacity of serum from i.m. DNA vaccinated  
carp. Serum (n = 5/group) was collected from vaccinated [pcDNA3-spring 
viremia of carp virus (SVCV)-G] and non-vaccinated (pcDNA3) carp 
3 months after vaccination and used in a neutralization assay using the 
SVCV VR-1390 strain. Epithelioma papulosum cyprinid (EPC) cells  
were fixed and stained with crystal violet after 3 days of infection.  
(a) Quantification of the number of virus plaques per well. Box plots 
indicate the minimum, maximum, and average plaques count. The upper 
threshold on the number of counted plaques, indicating a fully infected 
well, was set at 100 plaques. Asterisk (*) (p < 0.05) indicates a significant 
difference between the pcDNA3 and the pcDNA3-SVCV-G group at the 
given dilution as assessed by an one-way ANOVA. (B) Representative 
pictures of wells containing non-infected EPCs monolayers (non-infected), 
EPC infected with SVCV only in the absence of carp serum (SVCV control), 
SVCV incubated with serum from pcDNA3 injected control fish (pcDNA3) or 
with serum from pcDNA3-SVCV-G vaccinated fish (pcDNA3-SVCV-G).
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of importance since protection against rhabdoviruses has been 
shown to strongly rely on the presence of neutralizing antibod­
ies, although they are not always present at detectable titers (24). 
While no clear inhibition of viral growth was observed when 
using the serum of pcDNA3 injected carp (non­vaccinated), a 
significant neutralizing capacity was observed in the serum of 
pcDNA3­SVCV­G injected carp (vaccinated) (Figures  4A,B). 
Although only at a serum dilution of 1:10 the number of plaques 
was significantly different from the controls, a clear decrease in 
viral plaques was observed also at the 1:100 dilution. This result 
shows that a single i.m. injection of DNA vaccine encoding for 
the SVCV G protein, is sufficient to induce virus neutralizing 
activity in the serum of vaccinated fish, which is most likely 
mediated by virus neutralizing antibodies.
Dna Vaccination against sVcV induces 
the Formation of sVcV-specific Zap70+  
T cells
We next investigated the presence of SVCV­specific T  cells 
in the blood of vaccinated fish. To this end, we analyzed the 
proliferative capacity of antigen­specific T  cells in  vitro. PBLs 
were isolated from carp 3 months after vaccination, stimulated 
in vitro with SVCV alone, or in combination with recombinant 
Ifnγ2 or Il10b. These two cytokines were selected for their 
known capacity to promote T cell proliferation in carp. As was 
reported before, carp Il10b promoted proliferation of “memory” 
T  cells in an in  vitro study using PBLs and HKLs from carp 
that survived an infection with the blood­borne parasite 
Trypanoplasma borreli (47). IFNγ enhances antigen­specific 
T  cell proliferation, and in ginbuna crucian carp (Carassius 
auratus langsdorfii) recombinant Ifnγrel was found to enhance 
numbers of CD4+ and CD8α+ T cells during allograft rejection 
(51). Furthermore, a concomitant upregulation of tbet, ifnγ1, 
and ifnγ2 was observed upon stimulation of leukocytes from 
multiple organs with phytohemagglutinin (56). However, the 
effect of recombinant Il10b and Ifnγ2 on virus­specific T cells 
generated upon DNA vaccination is still unknown.
Proliferation of Zap70+ cells from vaccinated fish was quan­
tified 6  days poststimulation. Proliferation of cells stimulated 
with recombinant Ifnγ2 or rIl10b alone did not differ between 
the non­vaccinated (pcDNA3) and vaccinated (pcDNA3­
SVCV­G) groups (Figure  5A) however, Il10b, but not Ifnγ2, 
induced proliferation in both groups. By contrast, stimulation 
with SVCV induced a proliferative response in the vaccinated 
group only, and the proliferation was further enhanced by co­
stimulation with Ifnγ2 (Figures 5A,B) and, to a lesser extent, 
by rIl10b. One­way ANOVA analysis showed that the overall 
proliferative response of Zap70+ T  cells significantly different 
between vaccinated and non­vaccinated fish.
A similar approach was used to measure the proliferation of 
Igm+ B cells in PBLs from vaccinated and non­vaccinated fish. 
This revealed a high proliferative response upon SVCV stimu­
lation in both groups and therefore, no significant differences 
were observed (data not shown). Altogether, these data indicate 
that i.m. DNA vaccination against SVCV induces the formation 
of T cells that recirculate in the blood of vaccinated fish 3 months 
FigUre 5 | DNA vaccination against spring viremia of carp virus (SVCV) induces the formation of virus-specific T cells. PBLs were isolated 3 months after 
vaccination from non-vaccinated (pcDNA3) and vaccinated (pcDNA3-SVCV-G) carp. Carboxyfluorescein succinimidyl ester (CFSE)-labeled PBLs were stimulated  
for 6 days at 27°C with recombinant Ifnγ2 (100 ng/mL) or Il10b (0.25 U/mL) alone, or in combination with SVCV (MOI of 25). As a control, conditioned medium  
was used. T-cells were identified using a cross-reactive anti-Zap70 antibody, and proliferation was analyzed by flow cytometry. (a) Percentages of proliferating 
Zap70+ T cells are expressed relative to the respective conditioned medium control after subtraction of the percentage of proliferating cells in the medium control. 
For each group, bars represent average and SD of n = 7 fish/stimulus, except for the Il10b stimulated samples for which n = 3 fish were used. Asterisk (*) indicates 
a significant differences between the pcDNA3 and pcDNA3-SVCV-G group as assessed by one-way ANOVA. (B) Representative histogram plots of CFSE-labeled 
Zap70+ T cells from non-vaccinated (pcDNA3, left panel) and vaccinated (pcDNA3-SVCV-G, right panel) carp of the experiment in panel (a).
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after vaccination and proliferate when restimulated in vitro with 
SVCV. This proliferation capacity can be further enhanced by 
Ifnγ2 and to a lesser extent by rIl10b. Whether these T cells are 
CD4+ and/or CD8+ will require further investigation.
DiscUssiOn
The efficacy of DNA vaccination to protect carp against SVCV 
has been controversial, mainly because it is notoriously difficult 
to set up challenge models with this virus. Here, we used an 
efficient bath challenge method, which likely mimics the natu­
ral infection, to demonstrate that i.m. injection of a plasmid 
encoding the SVCV G protein affords a high level of protection 
against SVCV. We did not only investigate the challenge method 
but also the plasmid dose, the temperature of vaccination and 
the age of the fish at the time of vaccination, taking into account 
that carp were found to be most susceptible to SVCV within 
the first 6 months of age. When investigating the local response 
induced by i.m. vaccination, our findings reveal a substantial 
recruitment of neutrophils and macrophages during the first 
2  weeks following vaccination. Cells expressing the SVCV­G 
protein were surrounded by leukocytes, progressively discon­
nected from the neighboring cells and likely targeted by an 
immune response. Furthermore, our data show that DNA vac­
cination leads to the presence of virus­neutralizing activity in 
the serum of vaccinated fish, which is most likely mediated by 
neutralizing antibodies, and to the presence of SVCV­specific 
T cells in the blood of vaccinated fish, which proliferate in vitro 
upon SVCV restimulation. Altogether, these responses are 
likely responsible for the long­term protection of carp observed 
3 months after vaccination upon challenge with SVCV via the 
natural route of infection.
Challenge models that comply with the natural route of 
infection are of utmost importance for the proper validation of 
protective effects of experimental vaccines. While intraperitoneal 
injections are often used because of their ease of standardiza­
tion, cohabitation, or bath challenges, although typically more 
difficult to standardize, better resemble the natural route of 
infection. Here, we report a standardized and reproducible 
bath challenge procedure for common carp based on prolonged 
(>30 h) exposure to SVCV (8 × 106 pfu/mL), typically leading 
to >90% mortality rates in juvenile carp. Previously reported 
bath challenge procedures for SVCV showed mortality rates of 
67–75%, possibly because of the relatively short exposure time 
(60 min) to the virus and a lower viral load used (5 × 103 pfu/mL) 
(23). In our hands, such short exposure to the virus led to much 
lower mortality, typically lower than 30%. While shorter bath 
challenges of a few hours may be preferred because of practical 
reasons, longer exposure times generally enhance antigen uptake 
and possibly vaccine effectiveness (57). Indeed, longer exposure 
time (>30  h) clearly improved the reproducibility of our bath 
challenge with SVCV. To test the efficacy of our DNA vaccine 
against SVCV, we used different temperatures for vaccination 
(23°C) and for viral challenge (15°C). Higher temperature at vac­
cination is crucial for a rapid onset of specific immune responses, 
especially for T cell help and antibody formation, and 23°C falls 
within the temperature range optimal for carp (58–61). Possibly, 
vaccination at higher temperature might have contributed 
to the formation of virus neutralizing antibodies, most likely 
responsible for the neutralizing activity observed in the serum of 
vaccinated fish. In agreement, carp kept at 10 and 15°C showed 
a delay in SVCV clearance from the blood and a delayed deve­
lopment of neutralizing antibodies, when compared with fish 
kept at 20°C (62). Conversely, a lower temperature is crucial for 
viral replication and 15°C falls within the temperature range 
optimal for SVCV, with typical field outbreaks in Spring and 
associated mortalities occurring at water temperatures between 
11–17°C. In fact, carp challenged at 20–22°C typically show no 
mortalities whereas carp challenged at 10–12°C showed 90% 
mortality (62, 63). In our hands, carp older than 9 months of age, 
when kept at 10°C, showed up to 30% mortality when challenged 
using our optimized challenge method (data not shown), while 
no mortality was observed when carp of the same age were chal­
lenged at 15°C (Figure 1B). Altogether, these data suggest that 
it is likely advantageous to vaccinate carp at high temperature, 
to allow for optimal development of protective response. Also 
in rainbow trout, temperature­dependent differences in the 
kinetics and immune compartment involved in the response 
have been described after DNA vaccination against VHSV (64). 
For example, neutralizing activity was observed in the plasma 
of fish DNA vaccinated at 15°C whereas negligible or no neu­
tralizing activity was detected in fish vaccinated at 10 and 5°C. 
In agreement, also the specificity of the protection was shown to 
be temperature dependent; in fact, only trout kept at 15°C and 
vaccinated with a DNA plasmid encoding the VHSV­G protein, 
and not those vaccinated with a plasmid encoding the IHNV­G 
protein, showed a specific protection against VHSV upon 
challenged 40 days later. Conversely, trout kept and vaccinated 
at 10 or 5°C showed a protection against a VHSV challenge 
independently of whether they were vaccinated with either of 
the VHSV­G or the IHNV­G DNA plasmids, suggesting a role 
for non­specific innate immune mechanisms.
We also studied how the “natural” resistance of carp to bath 
exposure to SVCV increased with age, leading to almost full 
resistance from 9 months onward, which might be related to the 
gradual increase of cross­reactive (natural) antibodies developing 
over time (65). Age­dependent susceptibility to rhabdoviruses 
has also been reported for rainbow trout and pike to VHSV (66) 
and for rainbow trout to IHNV (67). In fact, it is a general obser­
vation for many other pathogens in fish and other vertebrates 
(68). This underlines the necessity of vaccinating carp at a young 
but immune­competent age of 3  months (69) to overcome the 
age period when they are most sensitive to SVCV (3–6 months). 
Finally, our data also make clear the need to verify vaccine efficacy 
within the age period of susceptibility, using the natural route of 
infection. Our vaccination protocol based on a low dose (0.1–1 µg 
DNA/g of fish) of pcDNA3­SVCV­G, protected carp against a 
lethal bath challenge with SVCV 2.5  months after vaccination. 
Lower doses might be investigated since in rainbow trout, a dose of 
0.01 µg DNA/g of fish could protect against IHNV (70). Previous 
DNA vaccination studies in common carp required higher doses 
(10–25 µg DNA/g) and/or up to two booster injections (22, 23) 
but were still less successful in achieving protection against a 
subsequent SVCV challenge, possibly caused by vaccination at 
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a slightly lower temperature (20°C), or due to difference in the 
challenge protocol (challenge route, viral strain).
In our study, challenge at >2.5  months after vaccination 
indicates that the protection is most likely due to the virus 
specific immune response and based on immune memory. 
Indeed, the non­specific interferon­induced response that 
typically arises quickly after DNA vaccination, is generally 
short­lived (29, 71, 72). The importance of specific immunity 
in the protection is further supported by the induction of neu­
tralizing antibodies and the presence of virus­specific T cells 
in the blood of vaccinated fish. “Long­term” (>2.5  months) 
protective effects of DNA vaccination against SVCV remain 
to be investigated in carp and would be interesting from an 
immunological point of view. However, they seem to be of 
lower practical relevance because of the relatively short win­
dow of susceptibility that needs to be covered between the time 
of immune maturity (>3 months) and development of natural 
resistance against SVCV (>6–9 months).
Histological analysis of the muscle tissue after injection 
revealed a strong and rapid influx of leukocytes at the site of 
injection. This was largely damage­ and/or inflammation­driven 
rather than antigen­specific because it was also seen after 
injection of the empty plasmid. Yet, the influx of leukocytes 
into myocytes expressing the SVCV­G protein as well as the 
time­dependent condensation and degradation of SVCV­G­
expressing cells that were completely surrounded by leukocytes, 
was specific for the SVCV­G injected group. This supports the 
notion that SVCV­G­expressing cells can be seen by the host as 
non­self and can trigger both innate as well as SVCV­specific 
(adaptive) immune responses, at least in part similar to the one 
triggered by a natural virus infection (24). A similar elimina­
tion of myocytes expressing the vaccine antigen was observed 
in rainbow trout; lymphocytes and macrophages were found in 
close proximity and infiltrating the G protein­positive myocytes 
(73). In carp, the influx of leukocytes and the following inflam­
matory reaction at the site of injection is consistent with the 
general upregulation of pro­inflammatory genes observed in 
the groups injected with both, the control or vaccine plasmid. 
Few genes (cxcb1, ifnγ2, il6b, ifnφ1, and ifnφ2) among those 
investigated within our panel were upregulated specifically in 
the G protein­vaccinated group. Recombinant carp Cxcb was 
previously shown to stimulate chemotaxis of carp macrophages 
and granulocytes in vitro (74). Also recombinant Il6 has been 
shown to have synergistic effects on antigen­specific Igm 
responses of trout, in  vivo, when co­injected with inactivated 
infectious pancreatic necrosis virus (75).
The SVCV­G protein­induced upregulation of type­I inter­
ferons (ifnφ1 and ifnφ2) appears an intrinsic property of the 
G protein since it was also noted for IHNV in rainbow trout 
(26, 29) and for VHSV in Atlantic salmon (27) and rainbow trout 
(14, 76, 77). In salmonids, the antiviral interferon response appears 
to be G protein­specific because mx was found upregulated only 
after i.m vaccination with VHSV­G, but not with VHSV­N (28). 
In conclusion, although a limited number of genes were specifi­
cally upregulated by injection of the pcDNA3­SVCV­G vaccine 
plasmid, it cannot be excluded that the inflammation caused 
by the injection­related damage, by the plasmid backbone, and 
finally by the SVCV­G protein all contribute to the onset of a 
subsequent specific response toward the G protein.
Of interest, a rapid (7 days) influx of Igm+ and Igt+ B lym­
phocytes in the muscle of trout DNA vaccinated with VHSV­G 
(78), suggests a role not only for innate immune cells but also 
for B lymphocytes in the early response to vaccination. In carp, 
SVCV­G­specific upregulation of zap70 and igt1 gene expres­
sion was noted already at 3 days postvaccination, hinting at a 
role also in carp of adaptive immune cells in the initial response 
to DNA vaccination against SVCV. Alternatively, this early wave 
of B cells may indirectly contribute to fight the virus via cytokine 
production. The importance of B  cells in protection against 
SVCV could be confirmed by the detection of neutralizing 
activity, most likely mediated by neutralizing antibodies, in the 
serum of vaccinated, but not control carp. Indeed, neutralizing 
antibodies have also been reported in early studies following 
vaccination with inactivated SVCV (53, 62), although this could 
not be confirmed in a later study with inactivated SVCV (79).
We also examined whether DNA vaccination can induce a 
T cell response, which would lead to long lasting virus­specific 
clones. SVCV­G­specific upregulation of the pan T cell marker 
zap70 was noted at 3  days after vaccination. Previous studies 
already suggested a role for cell­mediated immune responses 
in the protection against SVCV, based on the upregulation of 
various T­cell markers after SVCV challenge in carp (80) and on 
a strong lymphocyte proliferation also in the absence of SVCV­
specific antibodies in goldfish (22). To gain further insights in 
the T  cell response upon DNA vaccination, we analyzed the 
proliferative capacity of (Zap70+) T  cells by stimulating PBLs 
from vaccinated carp with SVCV in vitro. We also examined the 
potential of two (recombinant) cytokines, Il10b and Ifnγ2, to 
modulate such proliferative response. Interleukin­10 can have 
multiple effects on B and T lymphocytes, including regulation 
of proliferation and differentiation [as reviewed in Ref. (81)], 
and carp Il10b was shown to promote survival and enhance 
proliferation of antigen­specific B and T  cells (47). Ifnγ2 has 
multiple effects and in carp was found to enhance antigen­
specific responses during in vitro stimulation of carp leukocytes 
and phagocytes (48). We observed an SVCV­specific T  cell 
proliferation in PBLs from vaccinated carp stimulated in vitro 
with SVCV, which could be enhanced by Il10b or Ifnγ2. Despite 
the large variation in the individual response of PBLs, in vitro 
restimulation with the virus led to an overall significantly higher 
proliferation of T  cells in PBLs isolated from vaccinated fish 
when compared with the overall T  cells proliferation in PBLs 
from non­vaccinated fish. This suggests that the frequency of 
peripheral SVCV­specific T  cells is higher in vaccinated than 
in non­vaccinated fish. Although the development of a cell­
mediated cytotoxicity response after DNA vaccination against 
VHSV has been described in rainbow trout (32), in this report 
we show for the first time virus­specific proliferation of carp 
T cells in vitro after a single low dose injection of DNA vaccine 
against SVCV. The presence of virus­specific T cells 3 months 
after vaccination raises the issue of the importance of a T cell­
dependent response after the recall: while it is often considered 
that viral particles provide a perfect matrix of repetitive antigens 
to induce T cell­independent B cell responses, it is possible that 
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T  cell help plays an important role in the immune response 
of vaccinated fish. The virus­specific T  cells present in vac­
cinated fish may also comprise cytotoxic T cells, of which the 
contribution to protection would have to be assessed in  vivo. 
The development of antibodies against specific subsets of T cells 
will allow for further investigation of the role of T cells in the 
establishment of protection against SVCV.
From our data, it appears that already a single low dose of 
the SVCV­G DNA vaccine is sufficient to trigger both arms of 
the adaptive immune system. Our data show that DNA vaccina­
tion against SVCV induces neutralizing antibodies and suggest 
that SVCV­specific T cells might contribute to the protection.
Altogether, we for the first time report on a fully protective 
G protein­based DNA vaccine in carp against SVCV. We also 
describe age­related susceptibility of carp to SVCV, an optimized 
bath challenge method, along with the characterization of local 
as well as systemic protective immune responses after i.m. DNA 
vaccination against SVCV. Our data provide new insights into 
the respective implication of B and T cells in the response to the 
vaccine: an early role for the adaptive immune response and a 
possible early recruitment of B and T cells to the site of injec­
tion. In a later phase of the response we showed the induction 
of neutralizing antibodies, and the presence of antigen­specific 
“memory” T  cells. This latter finding raises the issue of the 
relative importance of T cells in the response. Most likely the 
combination of humoral as well as cell­mediated responses is 
key to the success of the current DNA vaccine. Given the recent 
developments in legislation of DNA vaccines for aquaculture 
species, marked by the approval on the use of the CLYNAV 
vaccine against pancreatic disease in Atlantic salmon (6), our 
data might contribute to the increasing need to study DNA vac­
cines for fish and their underlying mechanisms of protection.
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